Status: Recruiting
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act on different proteins on the surface of cells of the immune system and trigger the immune system to destroy cancer cells. The drugs being studied in NSABP FC-13 are cemiplimab, fianlimab, and REGN7075.
Participants needed: 79
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: NSABP Foundation IncUpdated: Jun 12, 2026Locations: 9
Eligibility criteria
The patient must have consented to participate and, prior to beginning specific... [+18]
Colon cancer other than adenocarcinoma, e.g., sarcoma, lymphoma, carcinoid. [+20]